Inhibition:Article Title: HLXB9 activates IL6 in Hodgkin lymphoma cell lines and is regulated by PI3K signalling involving E2F3.
Article Snippet: .. Inhibition of secreted IL6 protein was performed using anti-IL6 antibody (R&D Systems, Wiesbaden, Germany) and for stimulation experiments IL6 protein was purchased from Strathmann Biotec AG (Hamburg, Germany). .. For analysis of signal transduction pathways, the following pharmacological inhibitors were used: AG490 (Biomol/Upstate Biotechnology, Hamburg, Germany), PD98059 (Sigma, Taufkirchen, Germany), rapamycin (ICN Biomedicals, Meckenheim, Germany), and wortmannin (Sigma).
Recombinant:Article Title: Tissue plasminogen activator induced by dengue virus infection of human endothelial cells.
Article Snippet: Ying-Huey Huang, Huan-Yao Lei, Hsiao-Sheng Liu, Yee-Shin Lin, Shun-Hua Chen, Ching-Chuan Liu, and Trai-Ming Yeh* Department of Microbiology and Immunology, College of Medicine, National Cheng Kung University, Tainan, Taiwan, R.O.C.. Department of Pediatrics, College of Medicine, National Cheng Kung University, Tainan, Taiwan, R.O.C.. Department of Medical Technology, College of Medicine, National Cheng Kung University, Tainan, Taiwan, R.O.C.
Activity Assay:Article Title: Tissue plasminogen activator induced by dengue virus infection of human endothelial cells.
Article Snippet: Ying-Huey Huang, Huan-Yao Lei, Hsiao-Sheng Liu, Yee-Shin Lin, Shun-Hua Chen, Ching-Chuan Liu, and Trai-Ming Yeh* Department of Microbiology and Immunology, College of Medicine, National Cheng Kung University, Tainan, Taiwan, R.O.C.. Department of Pediatrics, College of Medicine, National Cheng Kung University, Tainan, Taiwan, R.O.C.. Department of Medical Technology, College of Medicine, National Cheng Kung University, Tainan, Taiwan, R.O.C.
Western Blot:Article Title: CDKN1A is a target for phagocytosis-mediated cellular immunotherapy in acute leukemia
Article Snippet: .. The primary antibodies were used for: western blot (anti-p21 Waf1/Cip1 (12D1) (Cell signalling, Cat#2947), antiMyosin Light Chain 2 (MLC2) (Cell signalling, Cat#3672), anti-Phospho (Ser19) Myosin light chain 2 (MLC2S19*) (Cell signalling, Cat#3671), anti-!Tubulin (DM1A) (Cell signalling, Cat#3873), anti-!/"-Tubulin (Cell signalling, Cat#2148), anti-IL8 (Abcam, Cat#ab106350), anti-IRF5 (Abcam, Cat#ab21689), anti-IL" (Abcam, Cat#ab2105), anti-iNOS (Abcam, Cat#ab3523), anti-IL6 antibody (RD systems, CatAB-206-NA), anti-hSIRP! antibody (Invitrogen, Cat#PA1-30537), anti-GAPDH antibody (EMD Millipore, Cat#MAB374), anti-p53 (DO-1) antibody (Santa Cruz Biotechnology, Cat#sc-126)); immunofluorescence (anti-LAMP2 (H4B4) antibody (Santa Cruz Biotechnology, Cat#sc-18822), anti-hCD45 antibody (Invitrogen, Cat#MA5-37809, Clone: JE03-05), Alexa-Fluor 647 antihCD68 (BD Pharmingen, Cat#562111, Clone: Y1/82A), anti-iNOS (Abcam, Cat#ab3523)), flow cytometry (FITC anti-hCD47 (Invitrogen, Cat#11-0479-42, Clone: B6H12), APC anti-hSIRP! (Invitrogen, Cat#17-1729-42, Clone: 15-414), APC anti-mF4/80 (Invitrogen, Cat#17-4801-82, Clone: BM8), Alexa Fluor 700 anti-mMHC II (I-A/I-E) (Invitrogen, Cat#56-5321-82, Clone: M5/114.15.2), PE-Cyanine7 anti-hCD71 (Transferrin receptor) (Invitrogen, Cat#25-0719-42, Clone: OKT9), PE anti-hCD14 (eBioscience, Cat#12-0149-42, Clone: 61D3), APC/Cy7 anti-hCD11b (BioLegend, Cat#301342, Clone: ICRF44), PE anti-hCD34 (BioLegend, Cat#343606, Clone: 561), PE/ Dazzle 594 anti-hCD7 (BioLegend, Cat#343120, Clone: CD7-6B7), Alexa Fluor 647 anti-hCD163 (BD Pharmingen, Cat#562669, Clone: GHI/61), PE anti-hCD71 (BD Pharmingen, Cat#555537), FITC anti-hCD206 (BD Pharmingen, Cat#551135), PE-Cy7 anti-hCD56 (BD Pharmingen, Cat#560916, Clone: B159), FITC anti-hCD3 (BD Pharmingen, Cat#555339), APC anti-hCD20 (BD Pharmingen, Cat#559776, Lot#3060541), PE anti-hCD47 (BD Pharmingen, Cat#558046), V450 anti-mCD45 (BD Horizon, Cat#560501, Clone: 30- F11), APC anti-hCD45 (BD Pharmingen, Cat#555485) and BUV395 anti-hCD45 (BD Horizon, Cat#563792, Clone: HI30); in vitro and in vivo blocking assays (anti-hIFN# antibody (RD systems, Cat#MAB285, Clone: 25718) and inVivoMAb anti-human CD47 antibody (Bio Cell, Cat#BE0019-1, Clone: B6.H12)). .. Jurkat, MOLT4, CEM, HEL and K562, HEK293T cell lines were purchased from and validated by the American Type Culture Collection (ATCC).
Immunofluorescence:Article Title: CDKN1A is a target for phagocytosis-mediated cellular immunotherapy in acute leukemia
Article Snippet: .. The primary antibodies were used for: western blot (anti-p21 Waf1/Cip1 (12D1) (Cell signalling, Cat#2947), antiMyosin Light Chain 2 (MLC2) (Cell signalling, Cat#3672), anti-Phospho (Ser19) Myosin light chain 2 (MLC2S19*) (Cell signalling, Cat#3671), anti-!Tubulin (DM1A) (Cell signalling, Cat#3873), anti-!/"-Tubulin (Cell signalling, Cat#2148), anti-IL8 (Abcam, Cat#ab106350), anti-IRF5 (Abcam, Cat#ab21689), anti-IL" (Abcam, Cat#ab2105), anti-iNOS (Abcam, Cat#ab3523), anti-IL6 antibody (RD systems, CatAB-206-NA), anti-hSIRP! antibody (Invitrogen, Cat#PA1-30537), anti-GAPDH antibody (EMD Millipore, Cat#MAB374), anti-p53 (DO-1) antibody (Santa Cruz Biotechnology, Cat#sc-126)); immunofluorescence (anti-LAMP2 (H4B4) antibody (Santa Cruz Biotechnology, Cat#sc-18822), anti-hCD45 antibody (Invitrogen, Cat#MA5-37809, Clone: JE03-05), Alexa-Fluor 647 antihCD68 (BD Pharmingen, Cat#562111, Clone: Y1/82A), anti-iNOS (Abcam, Cat#ab3523)), flow cytometry (FITC anti-hCD47 (Invitrogen, Cat#11-0479-42, Clone: B6H12), APC anti-hSIRP! (Invitrogen, Cat#17-1729-42, Clone: 15-414), APC anti-mF4/80 (Invitrogen, Cat#17-4801-82, Clone: BM8), Alexa Fluor 700 anti-mMHC II (I-A/I-E) (Invitrogen, Cat#56-5321-82, Clone: M5/114.15.2), PE-Cyanine7 anti-hCD71 (Transferrin receptor) (Invitrogen, Cat#25-0719-42, Clone: OKT9), PE anti-hCD14 (eBioscience, Cat#12-0149-42, Clone: 61D3), APC/Cy7 anti-hCD11b (BioLegend, Cat#301342, Clone: ICRF44), PE anti-hCD34 (BioLegend, Cat#343606, Clone: 561), PE/ Dazzle 594 anti-hCD7 (BioLegend, Cat#343120, Clone: CD7-6B7), Alexa Fluor 647 anti-hCD163 (BD Pharmingen, Cat#562669, Clone: GHI/61), PE anti-hCD71 (BD Pharmingen, Cat#555537), FITC anti-hCD206 (BD Pharmingen, Cat#551135), PE-Cy7 anti-hCD56 (BD Pharmingen, Cat#560916, Clone: B159), FITC anti-hCD3 (BD Pharmingen, Cat#555339), APC anti-hCD20 (BD Pharmingen, Cat#559776, Lot#3060541), PE anti-hCD47 (BD Pharmingen, Cat#558046), V450 anti-mCD45 (BD Horizon, Cat#560501, Clone: 30- F11), APC anti-hCD45 (BD Pharmingen, Cat#555485) and BUV395 anti-hCD45 (BD Horizon, Cat#563792, Clone: HI30); in vitro and in vivo blocking assays (anti-hIFN# antibody (RD systems, Cat#MAB285, Clone: 25718) and inVivoMAb anti-human CD47 antibody (Bio Cell, Cat#BE0019-1, Clone: B6.H12)). .. Jurkat, MOLT4, CEM, HEL and K562, HEK293T cell lines were purchased from and validated by the American Type Culture Collection (ATCC).
Flow Cytometry:Article Title: CDKN1A is a target for phagocytosis-mediated cellular immunotherapy in acute leukemia
Article Snippet: .. The primary antibodies were used for: western blot (anti-p21 Waf1/Cip1 (12D1) (Cell signalling, Cat#2947), antiMyosin Light Chain 2 (MLC2) (Cell signalling, Cat#3672), anti-Phospho (Ser19) Myosin light chain 2 (MLC2S19*) (Cell signalling, Cat#3671), anti-!Tubulin (DM1A) (Cell signalling, Cat#3873), anti-!/"-Tubulin (Cell signalling, Cat#2148), anti-IL8 (Abcam, Cat#ab106350), anti-IRF5 (Abcam, Cat#ab21689), anti-IL" (Abcam, Cat#ab2105), anti-iNOS (Abcam, Cat#ab3523), anti-IL6 antibody (RD systems, CatAB-206-NA), anti-hSIRP! antibody (Invitrogen, Cat#PA1-30537), anti-GAPDH antibody (EMD Millipore, Cat#MAB374), anti-p53 (DO-1) antibody (Santa Cruz Biotechnology, Cat#sc-126)); immunofluorescence (anti-LAMP2 (H4B4) antibody (Santa Cruz Biotechnology, Cat#sc-18822), anti-hCD45 antibody (Invitrogen, Cat#MA5-37809, Clone: JE03-05), Alexa-Fluor 647 antihCD68 (BD Pharmingen, Cat#562111, Clone: Y1/82A), anti-iNOS (Abcam, Cat#ab3523)), flow cytometry (FITC anti-hCD47 (Invitrogen, Cat#11-0479-42, Clone: B6H12), APC anti-hSIRP! (Invitrogen, Cat#17-1729-42, Clone: 15-414), APC anti-mF4/80 (Invitrogen, Cat#17-4801-82, Clone: BM8), Alexa Fluor 700 anti-mMHC II (I-A/I-E) (Invitrogen, Cat#56-5321-82, Clone: M5/114.15.2), PE-Cyanine7 anti-hCD71 (Transferrin receptor) (Invitrogen, Cat#25-0719-42, Clone: OKT9), PE anti-hCD14 (eBioscience, Cat#12-0149-42, Clone: 61D3), APC/Cy7 anti-hCD11b (BioLegend, Cat#301342, Clone: ICRF44), PE anti-hCD34 (BioLegend, Cat#343606, Clone: 561), PE/ Dazzle 594 anti-hCD7 (BioLegend, Cat#343120, Clone: CD7-6B7), Alexa Fluor 647 anti-hCD163 (BD Pharmingen, Cat#562669, Clone: GHI/61), PE anti-hCD71 (BD Pharmingen, Cat#555537), FITC anti-hCD206 (BD Pharmingen, Cat#551135), PE-Cy7 anti-hCD56 (BD Pharmingen, Cat#560916, Clone: B159), FITC anti-hCD3 (BD Pharmingen, Cat#555339), APC anti-hCD20 (BD Pharmingen, Cat#559776, Lot#3060541), PE anti-hCD47 (BD Pharmingen, Cat#558046), V450 anti-mCD45 (BD Horizon, Cat#560501, Clone: 30- F11), APC anti-hCD45 (BD Pharmingen, Cat#555485) and BUV395 anti-hCD45 (BD Horizon, Cat#563792, Clone: HI30); in vitro and in vivo blocking assays (anti-hIFN# antibody (RD systems, Cat#MAB285, Clone: 25718) and inVivoMAb anti-human CD47 antibody (Bio Cell, Cat#BE0019-1, Clone: B6.H12)). .. Jurkat, MOLT4, CEM, HEL and K562, HEK293T cell lines were purchased from and validated by the American Type Culture Collection (ATCC).
In Vitro:Article Title: CDKN1A is a target for phagocytosis-mediated cellular immunotherapy in acute leukemia
Article Snippet: .. The primary antibodies were used for: western blot (anti-p21 Waf1/Cip1 (12D1) (Cell signalling, Cat#2947), antiMyosin Light Chain 2 (MLC2) (Cell signalling, Cat#3672), anti-Phospho (Ser19) Myosin light chain 2 (MLC2S19*) (Cell signalling, Cat#3671), anti-!Tubulin (DM1A) (Cell signalling, Cat#3873), anti-!/"-Tubulin (Cell signalling, Cat#2148), anti-IL8 (Abcam, Cat#ab106350), anti-IRF5 (Abcam, Cat#ab21689), anti-IL" (Abcam, Cat#ab2105), anti-iNOS (Abcam, Cat#ab3523), anti-IL6 antibody (RD systems, CatAB-206-NA), anti-hSIRP! antibody (Invitrogen, Cat#PA1-30537), anti-GAPDH antibody (EMD Millipore, Cat#MAB374), anti-p53 (DO-1) antibody (Santa Cruz Biotechnology, Cat#sc-126)); immunofluorescence (anti-LAMP2 (H4B4) antibody (Santa Cruz Biotechnology, Cat#sc-18822), anti-hCD45 antibody (Invitrogen, Cat#MA5-37809, Clone: JE03-05), Alexa-Fluor 647 antihCD68 (BD Pharmingen, Cat#562111, Clone: Y1/82A), anti-iNOS (Abcam, Cat#ab3523)), flow cytometry (FITC anti-hCD47 (Invitrogen, Cat#11-0479-42, Clone: B6H12), APC anti-hSIRP! (Invitrogen, Cat#17-1729-42, Clone: 15-414), APC anti-mF4/80 (Invitrogen, Cat#17-4801-82, Clone: BM8), Alexa Fluor 700 anti-mMHC II (I-A/I-E) (Invitrogen, Cat#56-5321-82, Clone: M5/114.15.2), PE-Cyanine7 anti-hCD71 (Transferrin receptor) (Invitrogen, Cat#25-0719-42, Clone: OKT9), PE anti-hCD14 (eBioscience, Cat#12-0149-42, Clone: 61D3), APC/Cy7 anti-hCD11b (BioLegend, Cat#301342, Clone: ICRF44), PE anti-hCD34 (BioLegend, Cat#343606, Clone: 561), PE/ Dazzle 594 anti-hCD7 (BioLegend, Cat#343120, Clone: CD7-6B7), Alexa Fluor 647 anti-hCD163 (BD Pharmingen, Cat#562669, Clone: GHI/61), PE anti-hCD71 (BD Pharmingen, Cat#555537), FITC anti-hCD206 (BD Pharmingen, Cat#551135), PE-Cy7 anti-hCD56 (BD Pharmingen, Cat#560916, Clone: B159), FITC anti-hCD3 (BD Pharmingen, Cat#555339), APC anti-hCD20 (BD Pharmingen, Cat#559776, Lot#3060541), PE anti-hCD47 (BD Pharmingen, Cat#558046), V450 anti-mCD45 (BD Horizon, Cat#560501, Clone: 30- F11), APC anti-hCD45 (BD Pharmingen, Cat#555485) and BUV395 anti-hCD45 (BD Horizon, Cat#563792, Clone: HI30); in vitro and in vivo blocking assays (anti-hIFN# antibody (RD systems, Cat#MAB285, Clone: 25718) and inVivoMAb anti-human CD47 antibody (Bio Cell, Cat#BE0019-1, Clone: B6.H12)). .. Jurkat, MOLT4, CEM, HEL and K562, HEK293T cell lines were purchased from and validated by the American Type Culture Collection (ATCC).
In Vivo:Article Title: CDKN1A is a target for phagocytosis-mediated cellular immunotherapy in acute leukemia
Article Snippet: .. The primary antibodies were used for: western blot (anti-p21 Waf1/Cip1 (12D1) (Cell signalling, Cat#2947), antiMyosin Light Chain 2 (MLC2) (Cell signalling, Cat#3672), anti-Phospho (Ser19) Myosin light chain 2 (MLC2S19*) (Cell signalling, Cat#3671), anti-!Tubulin (DM1A) (Cell signalling, Cat#3873), anti-!/"-Tubulin (Cell signalling, Cat#2148), anti-IL8 (Abcam, Cat#ab106350), anti-IRF5 (Abcam, Cat#ab21689), anti-IL" (Abcam, Cat#ab2105), anti-iNOS (Abcam, Cat#ab3523), anti-IL6 antibody (RD systems, CatAB-206-NA), anti-hSIRP! antibody (Invitrogen, Cat#PA1-30537), anti-GAPDH antibody (EMD Millipore, Cat#MAB374), anti-p53 (DO-1) antibody (Santa Cruz Biotechnology, Cat#sc-126)); immunofluorescence (anti-LAMP2 (H4B4) antibody (Santa Cruz Biotechnology, Cat#sc-18822), anti-hCD45 antibody (Invitrogen, Cat#MA5-37809, Clone: JE03-05), Alexa-Fluor 647 antihCD68 (BD Pharmingen, Cat#562111, Clone: Y1/82A), anti-iNOS (Abcam, Cat#ab3523)), flow cytometry (FITC anti-hCD47 (Invitrogen, Cat#11-0479-42, Clone: B6H12), APC anti-hSIRP! (Invitrogen, Cat#17-1729-42, Clone: 15-414), APC anti-mF4/80 (Invitrogen, Cat#17-4801-82, Clone: BM8), Alexa Fluor 700 anti-mMHC II (I-A/I-E) (Invitrogen, Cat#56-5321-82, Clone: M5/114.15.2), PE-Cyanine7 anti-hCD71 (Transferrin receptor) (Invitrogen, Cat#25-0719-42, Clone: OKT9), PE anti-hCD14 (eBioscience, Cat#12-0149-42, Clone: 61D3), APC/Cy7 anti-hCD11b (BioLegend, Cat#301342, Clone: ICRF44), PE anti-hCD34 (BioLegend, Cat#343606, Clone: 561), PE/ Dazzle 594 anti-hCD7 (BioLegend, Cat#343120, Clone: CD7-6B7), Alexa Fluor 647 anti-hCD163 (BD Pharmingen, Cat#562669, Clone: GHI/61), PE anti-hCD71 (BD Pharmingen, Cat#555537), FITC anti-hCD206 (BD Pharmingen, Cat#551135), PE-Cy7 anti-hCD56 (BD Pharmingen, Cat#560916, Clone: B159), FITC anti-hCD3 (BD Pharmingen, Cat#555339), APC anti-hCD20 (BD Pharmingen, Cat#559776, Lot#3060541), PE anti-hCD47 (BD Pharmingen, Cat#558046), V450 anti-mCD45 (BD Horizon, Cat#560501, Clone: 30- F11), APC anti-hCD45 (BD Pharmingen, Cat#555485) and BUV395 anti-hCD45 (BD Horizon, Cat#563792, Clone: HI30); in vitro and in vivo blocking assays (anti-hIFN# antibody (RD systems, Cat#MAB285, Clone: 25718) and inVivoMAb anti-human CD47 antibody (Bio Cell, Cat#BE0019-1, Clone: B6.H12)). .. Jurkat, MOLT4, CEM, HEL and K562, HEK293T cell lines were purchased from and validated by the American Type Culture Collection (ATCC).
Blocking Assay:Article Title: CDKN1A is a target for phagocytosis-mediated cellular immunotherapy in acute leukemia
Article Snippet: .. The primary antibodies were used for: western blot (anti-p21 Waf1/Cip1 (12D1) (Cell signalling, Cat#2947), antiMyosin Light Chain 2 (MLC2) (Cell signalling, Cat#3672), anti-Phospho (Ser19) Myosin light chain 2 (MLC2S19*) (Cell signalling, Cat#3671), anti-!Tubulin (DM1A) (Cell signalling, Cat#3873), anti-!/"-Tubulin (Cell signalling, Cat#2148), anti-IL8 (Abcam, Cat#ab106350), anti-IRF5 (Abcam, Cat#ab21689), anti-IL" (Abcam, Cat#ab2105), anti-iNOS (Abcam, Cat#ab3523), anti-IL6 antibody (RD systems, CatAB-206-NA), anti-hSIRP! antibody (Invitrogen, Cat#PA1-30537), anti-GAPDH antibody (EMD Millipore, Cat#MAB374), anti-p53 (DO-1) antibody (Santa Cruz Biotechnology, Cat#sc-126)); immunofluorescence (anti-LAMP2 (H4B4) antibody (Santa Cruz Biotechnology, Cat#sc-18822), anti-hCD45 antibody (Invitrogen, Cat#MA5-37809, Clone: JE03-05), Alexa-Fluor 647 antihCD68 (BD Pharmingen, Cat#562111, Clone: Y1/82A), anti-iNOS (Abcam, Cat#ab3523)), flow cytometry (FITC anti-hCD47 (Invitrogen, Cat#11-0479-42, Clone: B6H12), APC anti-hSIRP! (Invitrogen, Cat#17-1729-42, Clone: 15-414), APC anti-mF4/80 (Invitrogen, Cat#17-4801-82, Clone: BM8), Alexa Fluor 700 anti-mMHC II (I-A/I-E) (Invitrogen, Cat#56-5321-82, Clone: M5/114.15.2), PE-Cyanine7 anti-hCD71 (Transferrin receptor) (Invitrogen, Cat#25-0719-42, Clone: OKT9), PE anti-hCD14 (eBioscience, Cat#12-0149-42, Clone: 61D3), APC/Cy7 anti-hCD11b (BioLegend, Cat#301342, Clone: ICRF44), PE anti-hCD34 (BioLegend, Cat#343606, Clone: 561), PE/ Dazzle 594 anti-hCD7 (BioLegend, Cat#343120, Clone: CD7-6B7), Alexa Fluor 647 anti-hCD163 (BD Pharmingen, Cat#562669, Clone: GHI/61), PE anti-hCD71 (BD Pharmingen, Cat#555537), FITC anti-hCD206 (BD Pharmingen, Cat#551135), PE-Cy7 anti-hCD56 (BD Pharmingen, Cat#560916, Clone: B159), FITC anti-hCD3 (BD Pharmingen, Cat#555339), APC anti-hCD20 (BD Pharmingen, Cat#559776, Lot#3060541), PE anti-hCD47 (BD Pharmingen, Cat#558046), V450 anti-mCD45 (BD Horizon, Cat#560501, Clone: 30- F11), APC anti-hCD45 (BD Pharmingen, Cat#555485) and BUV395 anti-hCD45 (BD Horizon, Cat#563792, Clone: HI30); in vitro and in vivo blocking assays (anti-hIFN# antibody (RD systems, Cat#MAB285, Clone: 25718) and inVivoMAb anti-human CD47 antibody (Bio Cell, Cat#BE0019-1, Clone: B6.H12)). .. Jurkat, MOLT4, CEM, HEL and K562, HEK293T cell lines were purchased from and validated by the American Type Culture Collection (ATCC).
other:Article Title: SARS-CoV-2 M Protein Facilitates Malignant Transformation of Breast Cancer Cells
Article Snippet: In order to inhibit the inflammatory cytokines, neutralizing antibodies were added to conditioned medium, including human anti-TNFα antibody (MAB210, R&D Systems, Minneapolis, MN, USA), anti-IL6 antibody (MAB2061, R&D Systems) and anti-IL8 antibody (MAB208, R&D Systems) at concentrations of 10 μg/ml, 5 μg/ml and 5 μg/ml respectively.
|
R&D Systems is a verified supplier 
R&D Systems manufactures this product 